Ramon Parsons, MD, PhD
img_Ramon Parsons
PROFESSOR & CHAIR | Oncological Sciences
PROFESSOR | Medicine, Hematology and Medical Oncology
Research Topics
Cancer, Cancer Genetics, Chromatin, Diabetes, Epigenetics, Epithelial Cells, Gene Regulation, Growth Factors and Receptors, IGF-1 Receptor, Insulin, Insulin Receptor, Knockout Mice, Lipid Signaling, Mass Spectrometry, Microarray, Molecular Biology, Oncogenes, Phosphorylation, Protein Kinases, Protein Phosphatases, Tumor Suppressor Genes, Tumorigenesis
Multi-Disciplinary Training Area
Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT)
The Parsons laboratory seeks to investigate tumor suppressor and oncogene signaling pathways that are altered in human solid tumors using a multidisciplinary approach that includes genetics, biochemistry, bioinformatics, and pathology.  Thematic topics that are currently under investigation include dissection of the regulation and function of the PTEN tumor suppressor, determination of the impact of altered PTEN signals in cancer progression and altered energy metabolism, molecular pathogenesis of breast carcinoma initiation and progression, and examination of epigenetic and chromatin reprogramming as consequence of altered cancer signal pathways.  Past accomplishments include discovery of PTEN, elucidation of the frequent alteration of the PI3K/PTEN pathway in a wide variety of cancers, generation of mouse models of cancer due to PTEN mutation, and identification of PREX2 as a regulator of PTEN function.

Visit the Parsons Laboratory

AB, Columbia University

MD, PhD, State University of New York at Stony Brook

Postdoctoral Training, Johns Hopkins University


Elected, National Academy of Medicine


Elected, Society of Scholars of the Johns Hopkins University


AACR Outstanding Investigator Award for Breast Cancer Research

PTEN and Cancer

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Parsons during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Therapten, Inc

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.